15 May 1997

Medicinal Applications of Delta-9-Tetrahydrocannabinol and Marijuana

Publication: Annals of Internal Medicine
Volume 126, Number 10


The use of crude marijuana for herbal medicinal applications is now being widely discussed in both the medical and lay literature.Ballot initiatives in California and Arizona have recently made crude marijuana accessible to patients under certain circumstances. As medicinal applications of pure forms of delta-9-tetrahydrocannabinol (THC) and crude marijuana are being considered, the most promising uses of any form of THC are to counteract the nausea associated with cancer chemotherapy and to stimulate appetite.
We evaluated the relevant research published between 1975 and 1996 on the medical applications, physical complications, and legal precedents for the use of pure THC or crude marijuana.Our review focused on the medical use of THC derivatives for nausea associated with cancer chemotherapy, glaucoma, stimulation of appetite, and spinal cord spasticity. Despite the toxicity of THC delivered in any form, evidence supports the selective use of pure THC preparations to treat nausea associated with cancer chemotherapy and to stimulate appetite. The evidence does not support the reclassification of crude marijuana as a prescribable medicine.

Get full access to this article

View all available purchase options and get full access to this article.


Ross SA, Elsohly MA. Constituents of Cannabis Sativa L. XXVIII. A review of the natural constituents: 1980-1994. J Pharm Sci. 1995; 4:1-10.
Poster DS, Penta JS, Bruno S, Macdonald JS. delta 9-tetrahydrocannabinol in clinical oncology. JAMA. 1981; 245:2047-52.
Vincent BJ, McQuiston DJ, Einhorn LH, Nagy CM, Brames MJ. Review of cannabinoids and their antiemetic effectiveness. Drugs. 1983; 25(Suppl 1):52-62.
Sallan SE, Zinberg NE, Frei E 3d. Antiemetic effect of delta-9-tetrahydrocannabinol in patients receiving cancer chemotherapy. N Engl J Med. 1975; 293:795-7.
Sallan SE, Cronin C, Zelen M, Zinberg NE. Antiemetics in patients receiving chemotherapy for cancer: a randomized comparison of delta-9-tetrahydrocannabinol and prochlorperazine. N Engl J Med. 1979; 302:135-8.
Chang AE, Shiling DJ, Stillman RC, Goldberg NH, Seipp CA, Barofsky I, et. al. Delta-9-tetrahydrocannabinol as an antiemetic in cancer patients receiving high-dose methotrexate. A prospective, randomized evaluation. Ann Intern Med. 1979; 91:819-24.
Frytak S, Moertel CG, O'Fallon JR, Rubin J, Creagan ET, O'Connell MJ, et al. Delta-9-tetrahydrocannabinol as an antiemetic for patients receiving cancer chemotherapy. A comparison with prochlorperazine and a placebo. Ann Intern Med. 1979; 91:825-30.
Kluin-Neleman JC, Neleman FA, Meuwissen OJ, Maes RA. delta-9-tetrahydrocannabinol (THC) as an antiemetic in patients treated with cancer chemotherapy: a double-blind cross-over trial against placebo. Vet Hum Toxicol. 1979; 21:338-40.
Ekert H, Waters KD, Jurk IH, Mobilia J, Loughnan P. Amelioration of cancer chemotherapy-induced nausea and vomiting by delta-9-tetrahydrocannabinol. Med J Aust. 1979; 2:657-9.
Lucas VS Jr, Laszlo J. delta-9-Tetrahydrocannabinol for refractory vomiting induced by cancer chemotherapy. JAMA. 1980; 243:1241-3.
Orr LE, McKernan JF, Bloome B. Antiemetic effect of tetrahydrocannabinol. Compared with placebo and prochlorperazine in chemotherapy-associated nausea and emesis. Arch Intern Med. 1980; 140:1431-3.
Gralla RJ, Tyson LB, Clark RA, Bordin LA, Kelsen DP, Kalman LB. Antiemetic trials with high dose metoclopramide: superiority over THC, and preservation of efficacy in subsequent chemotherapy courses [Abstract]. Proceedings of the American Society of Clinical Oncology. 1982; 1:58.
Ungerleider JT, Andrysiak T, Fairbanks L, Goodnight J, Sarna G, Jamison K. Cannabis and cancer chemotherapy: a comparison of oral delta-9-tetrahydrocannabinol and prochlorperazine. Cancer. 1982; 50:636-45.
Levitt M, Faiman C, Hawks R, Wilson A. Randomized double blind comparison of delta-9-tetrahydrocannabinol and marijuana as chemotherapy antiemetics [Abstract]. Proceedings of the Annual Meeting of the American Society of Clinical Oncology, Toronto, 6-8 May 1984. 1984; 3:91.
Vinciguerra V, Moore T, Brennan E. Inhalation marijuana as an antiemetic for cancer chemotherapy. N Y State J Med. 1988; 88:525-7.
Lane M, Vogel CL, Ferguson J, Krasnow S, Saiers JL, Hamm J, et al. Dronabinol and prochlorperazine in combination for treatment of cancer chemotherapy-induced nausea and vomiting. J Pain Symptom Manage. 1991; 6:352-9.
Hindrik WJ, O'Hanlon JF. Marijuana and actual driving performance. Washington, DC: U.S. Department of Transportation. 1993. Report no. DOT HS 808 078.
Nelson K, Walsh D, Deeter P, Sheehan F. A phase II study of delta-9-tetrahydrocannabinol for appetite stimulation in cancer-associated anorexia. J Palliat Care. 1994; 10:14-8.
Beal JE, Olson R, Laubenstein L, Morales JO, Bellman P, Yangco B, et al. Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS. J Pain Symptom Manage. 1995; 10:89-97.
Mattes RD, Engelman K, Shaw LM, Elsohly MA. Cannabinoids and appetite stimulation. Pharmacol Biochem Behav. 1994; 49:187-95.
Elsohly MA, Harland E, Murphy JC, Wirth P, Waller CW. Cannabinoids in glaucoma: a primary screening procedure. J Clin Pharmacol. 1981; 21:472S-8S.
Elsohly MA, Harland EC, Benigni DA, Waller CW. Cannabinoids in glaucoma II: the effect of different cannabinoids on intraocular pressure of the rabbit. Curr Eye Res. 1984; 3:841-50.
McLaughlin MA, Chiou GC. A synopsis of recent developments in antiglaucoma drugs. J Ocul Pharmacol. 1985; 1:101-21.
Merritt JC, Crawford WJ, Alexander PC, Anduze AL, Gelbart SS. Effect of marijuana on intraocular and blood pressure in glaucoma. Ophthalmology. 1980; 87:222-8.
Mechoulam R, Feigenbaum JJ. Towards cannabinoid drugs. In: Ellis GP, West GB, eds. Progress in Medicinal Chemistry. v 24. Oxford, UK: Elsevier; 1987.
Meinck HM, Schonle PW, Conrad B. Effect of cannabinoids on spasticity and ataxia in multiple sclerosis. J Neurol. 1989; 236:120-2.
Greenberg HS, Werness AS, Pugh JE, Andrus RO, Anderson DJ, Domino MD. Short-term effects of smoking marijuana on balance in patients with multiple sclerosis and normal volunteers. Clin Pharmacol Ther. 1994; 55:324-8.
Kiplinger GF, Manno JE, Rodda BE, Forney RB. Dose-response analysis of the effects of tetrahydrocannabinol in man. Clin Pharmacol Ther. 1971; 12:650-7.
Block RI, Wittenborn JR. Marijuana effects on the speed of memory retrieval in the letter-matching task. Int J Addict. 1986; 21:281-5.
Leon-Carrion J. Mental performance in long-term heavy cannabis use: a preliminary report. Psychol Rep. 1990; 67:947-52.
Murray JB. Marijuana's effects on human cognitive functions, psychomotor functions, and personality. J Gen Psychol. 1986; 113:23-55.
Schwartz RH, Gruenewald PJ, Klitzner M, Fedio P. Short-term memory impairment in cannabis-dependent adolescents. Am J Dis Child. 1989; 143:1214-9.
Varma VK, Malhotra AK, Dang R, Das K, Nehra R. Cannabis and cognitive functions: a prospective study. Drug Alcohol Depend. 1988; 21:147-52.
Solowij N, Michie PT, Fox AM. Differential impairments of selective attention due to frequency and duration of cannabis use. Biol Psychiatry. 1995; 37:731-9.
Solowij N. Do cognitive impairments recover following cessation of cannabis use? Life Sci. 1995; 5:2119-26.
Pope HG Jr, Yurgelun-Todd D. The residual cognitive effects of heavy marijuana use in college students. JAMA. 1996; 275:521-7.
Leirer VO, Yesavage JA, Morrow DG. Marijuana carry-over effects on psychomotor performance: a chronicle of research. In: Nahas GG, Latour C, eds. Cannabis: Physiopathology, Epidemiology, Detection. Boca Raton, FL: CRC Pr; 1993:47-60.
Yesavage JA, Leirer VO, Denari M, Hollister LE. Carry-over effects of marijuana intoxication on aircraft pilot performance: a preliminary report. Am J Psychiatry. 1985; 142:1325-9.
Brookoff D, Campbell EA, Shaw LM. The underreporting of cocainerelated trauma: drug abuse warning network reports vs. hospital toxicology tests. Am J Public Health. 1993; 83:369-71.
Gerostamoulos J, Drummer OH. Incidence of psychoactive cannabinoids in drivers killed in motor vehicle accidents. J Forensic Sci. 1993; 38:649-56.
Gjerde H, Kinn G. Impairment in drivers due to cannabis in combination with other drugs. Forensic Sci Int. 1991; 50:57-60.
Kirby JM, Maull KI, Fain W. Comparability of alcohol and drug use in injured drivers. South Med J. 1992; 85:800-2.
Marzuk PM, Tardiff K, Leon AC, Stajic M, Morgan EB, Mann JJ. Prevalence of recent cocaine use among motor vehicle fatalities in New York City. JAMA. 1990; 263:250-6.
Soderstrom CA, Tritillis AL, Shankar BS, Clark WE, Cowley A. Marijuana and alcohol use among 1023 trauma patients. In: Nahas GG, Latour C, eds. Cannabis: Physiopathology, Epidemiology, Detection. Boca Raton, FL: CRC Pr; 1993:79-91.
Nahas CG. Historical outlook of the psychopathology of cannabis. In: Nahas GG, Latour C, eds. Cannabis: Physiopathology, Epidemiology, Detection. Boca Raton, FL: CRC Pr; 1993:95-9.
Mathers DC, Ghodse AH. Cannabis and psychotic illness. Br J Psychiatry. 1992; 161:648-53.
Solomons K, Neppe VM, Kuyl JM. Toxic cannabis psychosis is a valid entity. S Afr Med J. 1990; 78:476-81.
Hoffman D, Brunneman DK, Gori GB, Wynder EL. On the carcinogenicity of marijuana smoke. Recent Advances in Phytochemistry. 1975; 9:63-81.
Wu TC, Tashkin DP, Djahed B, Rose JE. Pulmonary hazards of smoking marijuana as compared with tobacco. N Engl J Med. 1988; 318:347-51.
Ungerleider JT, Andrysiak T, Tashkin DP, Gale RP. Contamination of marijuana cigarettes with pathogenic bacteria-possible source of infection in cancer patients. Cancer Treat Rep. 1982; 66:589-90.
Taylor DN, Wachsmuth IK, Shangkuan YH, Schmidt EV, Barrett TJ, Schrader JS, et al. Salmonellosis associated with marijuana: a multistate outbreak traced by plasmid fingerprinting. N Engl J Med. 1982; 306:1249-54.
Fleisher M, Winawer SJ, Zauber AG. Aspergillosis and marijuana [Letter]. Ann Intern Med. 1991; 115:578-9.
Tashkin DP, Calvarese BM, Simmons MS, Shapiro BJ. Respiratory status of seventy-four habitual marijuana smokers. Chest. 1980; 78:699-706.
Tashkin DP, Shapiro BJ, Lee YE, Harper CE. Subacute effects of heavy marijuana smoking on pulmonary function in healthy men. N Engl J Med. 1976; 294:125-9.
Tashkin DP, Simmons M, Clark V. Effect of habitual smoking of marijuana alone and with tobacco on nonspecific airways hyperreactivity. J Psychoactive Drugs. 1988; 20:21-5.
Tashkin DP, Coulson AH, Clark VA, Simmons M, Bourque LB, Duann S, et al. Respiratory symptoms and lung function in habitual heavy smokers of marijuana alone, smokers of marijuana and tobacco, smokers of tobacco alone, and nonsmokers. Am Rev Respir Dis. 1987; 135:209-16.
Barbers RG, Gong H Jr, Tashkin DP, Oishi J, Wallace JM. Differential examination of bronchoalveolar lavage cells in tobacco cigarette and marijuana smokers. Am Rev Respir Dis. 1987; 135:1271-5.
Fligiel SE, Venkat H, Gong H Jr, Tashkin DP. Bronchial pathology in chronic marijuana smokers: a light and electron microscopic study. J Psychoactive Drugs. 1988; 20:33-42.
Sherman MP, Aeberhard EE, Wong VZ, Simmons MS, Roth MD, Tashkin DP. Effects of smoking marijuana, tobacco or cocaine alone or in combination on DNA damage in human alveolar macrophages. Life Sci. 1995; 56:2201-7.
Cabral GA, Vasquez R. delta-9-tetrahydrocannabinol suppresses macrophage extrinsic antiherpesvirus activity. Proc Soc Exp Biol Med. 1992; 199:255-8.
Tashkin DP. Is frequent marijuana smoking harmful to health? [Editorial] West J Med. 1993; 158:635-7.
Gross G, Roussaki A, Ikenberg H, Drees N. Genital warts do not respond to systemic recombinant interferon alfa-2a treatment during cannabis consumption. Dermatologica. 1991; 183:203-7.
Cabral GA, Vasquez R. delta-9-Tetrahydrocannabinol suppresses macrophage extrinsic anti-herpesvirus activity. In: Nahas GG, Latour C, eds. Cannabis: Physiopathology, Epidemiology, Detection. Boca Raton, FL: CRC Pr; 1993:137-53.
Specter SC, Klein TW, Newton C, Mondragon M, Widen R, Friedman H. Marijuana effects on immunity: suppression of human natural killer cell activity by delta-9-tetrahydrocannabinol. Int J Immunopharmacol. 1986; 8:741-5.
Murison G, Chubb CB, Maeda S, Gemmell MA, Huberman E. Cannabinoids induce incomplete maturation of cultured human leukemia cells. Proc Natl Acad Sci. U S A. 1987; 84:5414-8.
Fried PA. Marijuana use by pregnant women: neurobehavioral effects in neonates. Drug Alcohol Depend. 1980; 6:415-24.
Fried PA, Watkinson B, Willan A. Marijuana use during pregnancy and decreased length of gestation. Am J Obstet Gynecol. 1984; 150:23-7.
Hingson R, Alpert JJ, Day N, Dooling E, Kayne H, Morelock S, et al. Effects of maternal drinking and marijuana use on fetal growth and development. Pediatrics. 1982; 70:539-46.
Kline J, Stein Z, Hutzler J. Cigarettes, alcohol and marijuana: varying associations with birthweight. Int J Epidemiol. 1987; 16:44-51.
Zimmerman S, Zimmerman AM. Genetic effects of marijuana. Int J Addict. 1990-91; 25:19-33.
Zuckerman B, Frank DA, Hingson R, Amaro H, Levenson SM, Kayne H, et. al. Effects of maternal marijuana and cocaine use on fetal growth. N Engl J Med. 1989; 320:762-8.
Robison LL, Buckley JD, Daigle AE, Wells R, Benjamin D, Arthur DC. Maternal drug use and risk of childhood non-lymphoblastic leukemia among offspring. An epidemiologic investigation implicating marijuana (a report from the Childrens Cancer Study Group). Cancer. 1989; 63:1904-11.
Day NL, Richardson GA, Goldschmidt L, Robles N, Taylor PM, Stoffer DS, et al. Effect of prenatal marijuana exposure on the cognitive development of offspring at age three. Neurotoxicol Teratol. 1994; 16:169-75.
Dahl RE, Scher MS, Williamson DE, Robles N, Day N. A longitudinal study of prenatal marijuana use. Effects on sleep and arousal at age 3 years. Arch Pediatr Adolesc Med. 1995; 149:145-50.
Fried PA. The Ottawa Prenatal Prospective Study (OPPS): methodological issues and findings-it's easy to throw the baby out with the bath water. Life Sci. 1995; 56:2159-68.
Compton DR, Dewey WL, Martin BR. Cannabis dependence and tolerance production. Adv Alcohol Subst Abuse. 1990; 9:129-47.
Kaplan HB, Martin SS, Johnson RJ, Robbins CA. Escalation of marijuana use: application of a general theory of deviant behavior. J Health Soc Behav. 1986; 27:44-61.
Committee on Drug Abuse of the Council on Psychiatric Services. Position statement on psychoactive substance use and dependence: update on marijuana and cocaine. Am J Psychiatry. 1987; 144:698-702.
Miller NS, Gold MS. The diagnosis of marijuana (cannabis) dependence. J Subst Abuse Treat. 1989; 6:183-92.
Miller NS, Gold MS, Pottash AC. A 12-step treatment approach for marijuana (cannabis) dependence. J Subst Abuse Treat. 1989; 6:241-50.
Schwartz RH. Marijuana: an overview. Pediatr Clin North Am. 1987; 34:305-17.
Grinspoon L, Bakalar JB. Marijuana: The Forbidden Medicine. New Haven, CT: Yale Univ Pr; 1993.
Voth EA, Brookoff D. Book review of Marijuana: The Forbidden Medicine. Ann Intern Med. 1994; 120:348.
Young FL. Opinion and recommended ruling, marijuana rescheduling petition. U.S. Department of Justice, Drug Enforcement Administration. Docket 86-22. September 1988.
Bonner R. Marijuana rescheduling petitions. Federal Register. 1992:10499-508.
Alliance for Cannabis Therapeutics v. DEA. U.S. Court of Appeals for the District of Columbia. 92-1168. Petition for the review of controlled substance. February 1994.
Doblin RE, Kleiman MA. Marijuana as antiemetic medicine: a survey of oncologists' experiences and attitudes. J Clin Oncol. 1991; 9:1314-9.
Jurgensen K. Anti-drug focus keeps marijuana from the ill. USA Today. 18 July 1995:14A.
Grinspoon L, Bakalar JB. Marihuana as medicine. A plea for reconsideration. JAMA. 1995; 273:1875-6.
Schwartz RH, Beveridge RA. Marijuana as an antiemetic drug: how useful is it today? Opinions from clinical oncologists. J Addict Dis. 1994; 13:53-65.
Schwartz RH, Voth EA. Marijuana to prevent nausea and vomiting in cancer patients during the 90's: a survey of clinical oncologists. South Med J. 1997; 90:167-72.
Martin BR. The THC receptor and its antagonists. In: Nahas GG, Burks TF, eds. Drug Abuse in the Decade of the Brain. Amsterdam: IOS Pr; 1997:139-44.

Information & Authors


Published In

cover image Annals of Internal Medicine
Annals of Internal Medicine
Volume 126Number 1015 May 1997
Pages: 791 - 798


Published in issue: 15 May 1997
Published online: 15 August 2000




Eric A. Voth, MD
From the International Drug Strategy Institute, Topeka, Kansas; University of Kansas School of Medicine, Kansas City, Kansas; and Fairfax Hospital, Falls Church, Virginia.
Richard H. Schwartz, MD
From the International Drug Strategy Institute, Topeka, Kansas; University of Kansas School of Medicine, Kansas City, Kansas; and Fairfax Hospital, Falls Church, Virginia.
Acknowledgments: The authors thank the professional review committee of the International Drug Strategy Institute for review and helpful input and Lenora Kinsey for assistance with the literature search.
Corresponding Author: Eric A. Voth, MD, The International Drug Strategy Institute, 901 Garfield, Topeka, KS 66606.
Current Author Addresses: Dr. Voth: The International Drug Strategy Institute, 901 Garfield, Topeka, KS 66606.

Metrics & Citations



If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. For an editable text file, please select Medlars format which will download as a .txt file. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.


Download article citation data for:
Eric A. Voth, Richard H. Schwartz. Medicinal Applications of Delta-9-Tetrahydrocannabinol and Marijuana. Ann Intern Med.1997;126:791-798. doi:10.7326/0003-4819-126-10-199705150-00008

View More

Get Access

Login Options:

You will be redirected to to sign-in to Annals to complete your purchase.

Create your Free Account

You will be redirected to to create an account that will provide access to Annals.

View options


View PDF/ePub

Related in ACP Journals

Full Text

View Full Text







Copy the content Link

Share on social media